of this program has demonstrated “proof of concept” for large scale disease focused genomics and will move to an expanded phase in late 2009. In addition, under her leadership the NCI planned and deployed the Nanotechnology Alliance for Cancer, a major network in cancer nanotechnology dedicated to the development and application of nanotechnologies to areas ranging from new generation diagnostics to drug delivery and imaging. More recently, Dr. Barker led a planning effort to enable the convergence of the physical sciences (physics, mathematics, physical chemistry, and engineering) with cancer biology. As a result the NCI will establish a network of Physical Oncology Centers to provide physical scientists and cancer biologists the opportunity to collaboratively study cancer at all scales. All of these programs broadly engage the extramural cancer research communities.
She co-led with the FDA the establishment of the NCI–FDA Interagency Oncology Task Force (IOTF). The focus of the IOTF is the identification of scientific and process gaps in the regulatory pathways for cancer interventions—and joint science-based approaches to addressing these barriers. Dr. Barker also leads the NCI’s efforts in strategic international research programs in Latin America and China.
Dr. Barker has a long history in research and the leadership and management of advanced research and development in the academic, non-profit, and private sectors. She served as a senior executive at Battelle Memorial Institute for 18 years where she developed and led large groups of scientists and technical staff working in drug discovery and development, pharmacology, clinical trials, and biotechnology, including several NCI sponsored research programs. As a Senior Vice President at Battelle, she pioneered several programs in cancer research in collaboration with the NCI, including the use of advanced research models for evaluating new drug candidates and novel models for pharmacologic and toxicological evaluation. In the private sector, she was a co-founder and CEO of a public biotechnology company focused in experimental therapeutics development of novel agents to control reactive oxygen damage; and a private cancer technology company.
She has served as a member of the National Coalition of Cancer Research; a Partner and member of the Board of Directors of C-Change; chairperson of the C-Change Cancer Research Team; founding member of the Department of Defense (DOD) Breast Cancer Research Program (BCRP) Integration Panel and chairperson of the BCRP Integration Panel; in a number of capacities for the American Association for Cancer Research (AACR), including the Board of Directors and chairperson of the Public Science Policy and Legislative Affairs Committee for over 10 years; a member of the NCI’s Board of Scientific Counselors, Division of Cancer Etiology, and chairperson of the Cancer Center Support Review Study